Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

17190

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Non-Insulin-Dependent
High Risk for Cardiovascular Event

Interventions

DRUG: Dapagliflozin 10 mg
DRUG: Placebo tablet

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]